Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04661540 · ClinicalTrials.gov registry record · Phase 2
A Study of Auxora in Patients With Critical COVID-19 Pneumonia
A Phase 2 study, sponsored by CalciMedica.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04661540 is a Phase 2 study that was terminated before completion, run by CalciMedica. The registered enrollment target is 10 participants.
The verdict
NCT04661540, a Phase 2 study, was terminated before completion, sponsored by CalciMedica.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a single-blind study of Auxora in patients with critical COVID-19 pneumonia, consisting of up to 3 cohorts of escalating dose. The main goal was to assess pharmacodynamic parameters of immune response, while also assessing safety and tolerability of the drug in this patient population.
Interventions
- DRUG Placebo
- DRUG CM4620-IE (Injectable Emulsion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2021-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04661540
The ClinicalTrials.gov registry entry for NCT04661540 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CalciMedica, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04661540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04661540 about?
NCT04661540 is a clinical study titled "A Study of Auxora in Patients With Critical COVID-19 Pneumonia". This is a single-blind study of Auxora in patients with critical COVID-19 pneumonia, consisting of up to 3 cohorts of escalating dose. The main goal was to assess pharmacodynamic parameters of immune response, while also assessing safety and tolerability of the drug in this patient population.
What is the current status of trial NCT04661540?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-03-02. Estimated completion is 2021-12-21.
What interventions are being tested in trial NCT04661540?
The interventions under investigation include: Placebo (DRUG), CM4620-IE (Injectable Emulsion) (DRUG).
Who is sponsoring clinical trial NCT04661540?
This trial is sponsored by CalciMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.